PITTSBURGH, April 15 /PRNewswire/ -- Precision Therapeutics will present two abstracts at the upcoming American Association for Cancer Research (AACR) meeting to be held in Washington, D.C. April 17-21.
The abstract titled, “Analysis of Biological Pathways Associated with Epirubicin and/or Cyclophosphamide Response by Pathway Enrichment Analysis in Human Breast Cancers,” used ChemoFx(R) to determine responsiveness to two specific chemotherapy agents or the combination of these agents. Publicly available microarray data for these cell lines were compared with ChemoFx(R) results, and pathway enrichment analysis was employed to detect specific biochemical pathways associated with these drug responses.
“We are very pleased and honored to be presenting these two abstracts at the AACR meeting. Having this research accepted for publication is a tremendous milestone for cancer patients as well as for the advancement of genomic research in personalized medicine,” said Sean McDonald, CEO of Precision Therapeutics.
Precision Therapeutics, Inc.
